Protecting neurons may require different strategies depending on the disease, but these studies share a common goal: targeting the processes that drive neurological damage. In cerebral ischemia, β-hydroxybutyrate reduced brain injury in rats by limiting inflammation and shifting microglia toward a more protective state. In childhood dementia, researchers combined patient-derived brain cells with machine learning to identify existing drugs that may reduce neurodegenerative changes.
In ALS, researchers highlight neuroinflammation as an active driver of disease that may require treatments tailored to each patient’s inflammatory profile. Together, these findings reflect a growing shift toward more precise neuroprotection, using metabolic therapies, advanced drug screening, and targeted treatment strategies to preserve vulnerable neurons.
1. β-Hydroxybutyrate induces microglial M2 polarization by inhibiting the NF-κB/NLRP3 pathway to ameliorate cerebral ischemia–reperfusion injury
Using patient-derived stem cells from children with Sanfilippo syndrome, researchers created a human brain-cell model that reproduced key features of the disease, including lysosomal dysfunction and progressive neurodegeneration. A machine-learning-guided drug screen identified at least nine existing compounds that significantly reduced these disease-related changes within two weeks, highlighting promising candidates for faster therapeutic development.
2. Drug screen and machine learning predict neuroprotective agents in a preclinical human model of childhood dementia
In rats with cerebral ischemia–reperfusion injury, β-hydroxybutyrate (BHB) reduced brain infarct size and neurological deficits while suppressing the NF-κB/NLRP3 inflammatory pathway. BHB also shifted microglia toward a more anti-inflammatory M2 state, suggesting a potential neuroprotective strategy for limiting secondary brain damage after ischemic stroke.
The findings are preclinical and will require further studies to determine whether the same effects occur in humans.
3. Bridging the gap: neuroinflammation and the dawn of precision medicine in amyotrophic lateral sclerosis
A new review argues that neuroinflammation in ALS is not just a side effect of motor neuron loss, but a disease-modifying process that may differ by patient and disease stage. Rather than broadly suppressing the immune system, future treatments may use biomarkers to identify specific inflammatory subtypes and match patients with more targeted therapies.
If you’d like to stay informed of the latest publications and breakthroughs in neuron regeneration, join our email newsletter to the right (or below on mobile). We send out weekly updates with the latest papers and studies, as well as podcast episodes with the people driving Neuroregenerative breakthroughs.
